‘Unconscionable’: Pfizer, Moderna to rake in combined $93 billion in 2022 COVID vaccine sales

A report by health data analytics group, Airfinity, projects “unprecedented” sales and profits for Pfizer and Moderna in 2022. According to the People’s Vaccine Alliance, the companies are pricing their vaccines by as much as $41 billion above the estimated cost of production.

(Article by Megan Redshaw republished from ChildrensHealthDefense.org)

The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the dayIt’s free.

Vaccine makers Pfizer and Moderna are projected to generate combined sales of $93.2 billion in 2022 nearly twice the amount they’re expected to rake in this year, said Airfinity, a health data analytics group.

Airfinity put total market sales for COVID vaccines in 2022 at $124 billion, according to the Financial Times.

Pfizer vaccine sales are predicted to reach $54.5 billion in 2022, and Moderna’s will hit $38.7 billion. The estimates blow the earlier figures — $23.6 billion for Pfizer and $20 billion for Moderna — out of the water.

“The numbers are unprecedented,” Rasmus Beck Hansen, CEO of Airfinity, told the Financial Times.

Sales of the mRNA shots will continue to rise in 2022 due to boosters and countries stockpiling to ward off variants, Airfinity said.

Pfizer will generate 64% of its sales, and Moderna 75% of its sales, from high-income countries in 2022, the analysts predicted.

In April, Pfizer predicted 2021 COVID vaccine sales of $26 billion. After second-quarter results were reported, Pfizer upped the figure to $33.5 billion. Bernstein analyst Ronny Gal said the company could ring up an additional $10 billion in vaccine sales in 2021.

Gal wrote:

“The numbers are going to be much higher. The guidance of $33.5B reflects contracts signed to today which reflect total commitment to sell 2.1 million doses (at average price of $15.95). Pfizer notes they expect to manufacture 3 million doses. Presumably much of those will be sold as well, albeit at lower average price as consumption shifts to emerging markets. This is probably another $10 billion.”

“The second quarter was remarkable in a number of ways,” Pfizer CEO Albert Bourla said. “Most visibly, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented, with now more than a billion doses of BNT162b2 having been delivered globally.”

On a conference call, Bourla said that while “it’s very early to speak” about the company’s sales expectations for next year, he put Pfizer’s 2022 production capacity at 4 billion doses.

Read More

redditpinterestlinkedintumblrmail